Jump Financial’s Cytek Biosciences CTKB Stock Holding History

Jump Financial’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$656K	Buy	148,083 +119,191	+413%	+$509K	0.01%	1366
2026 Q1	$126K	Buy	+28,892	New	+$136K	﹤0.01%	1729
2024 Q4	–	Sell	-73,697	Closed	-$408K	–	1715
2024 Q3	$408K	Buy	+73,697	New	+$418K	0.01%	1185
2023 Q4	–	Sell	-43,404	Closed	-$240K	–	1863
2023 Q3	$240K	Buy	+43,404	New	+$348K	0.01%	1423
2023 Q2	–	Sell	-99,089	Closed	-$911K	–	1861
2023 Q1	$911K	Buy	99,089 +26,479	+36%	+$285K	0.04%	635
2022 Q4	$741K	Buy	+72,610	New	+$976K	0.04%	614
2022 Q2	–	Sell	-34,854	Closed	-$376K	–	1686
2022 Q1	$376K	Buy	+34,854	New	+$471K	0.02%	950

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jump Financial's CTKB Position: Q2 2026 in Review

Jump Financial increased its Cytek Biosciences (CTKB) stake by 413% in Q2 2026, buying an estimated $509K and bringing the position to 148,083 shares worth $656K. The position accounts for 0.01% of the portfolio, ranked #1366.

Jump Financial first reported a position in CTKB in Q1 2022 and has held it in 7 quarters since. The position peaked at $911K in Q1 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Jump Financial held 148,083 shares of Cytek Biosciences worth $656K as of Q2 2026.
Jump Financial bought 119,191 Cytek Biosciences shares in Q2 2026, an estimated $509K.
Cytek Biosciences made up 0.01% of Jump Financial's portfolio in Q2 2026, its #1366 holding.
Jump Financial first reported a position in Cytek Biosciences in Q1 2022 and has held it in 7 quarters since.
Jump Financial's Cytek Biosciences position peaked at $911K in Q1 2023.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.